Development of Custom Immunobead Assays for Neoantigen-Associated Autoantibodies to Prognosticate Response to Immunotherapy in Advanced Lung Cancer

Watch this 30-minute webinar presented by Dr. Jeff Borgia, Director of the Rush Cancer Center Biorepository, exploring the development of custom immunobead assays for advanced lung cancer treatment. Learn about innovative approaches to prognosticate immunotherapy responses through neoantigen-associated autoantibodies, addressing the critical need for improved treatment selection given lung cancer's 25% mortality rate. Discover how custom immunobead assays offer advantages over traditional immunohistochemistry methods, including faster turnaround times and the ability to analyze multiple immune response targets simultaneously. Gain insights into the practical applications of multiplex immunobead assays on the Luminex xMAP platform and understand how these developments can help stratify lung cancer patients for more effective immunotherapy treatments. Explore the evolution of cancer treatments from early PD-1 and PD-L1 therapies to current innovative approaches in biomarker development for personalized cancer treatment decisions.